Summit Therapeutics SMMT
NASDAQ SMMT
$16.75 +0.06 (+0.39%)
At close: Oct 2, 2026 · 4:00 PM EDT

Summit Therapeutics (SMMT) Non-Current Deffered Revenue (2019 - 2021)

Updated

Summit Therapeutics (SMMT) recorded Non-Current Deffered Revenue of $365,000 in Q2 2021, down 4.7% from the prior quarter.

Analysis

Summit Therapeutics (SMMT) Non-Current Deffered Revenue (2019 - 2021) Analysis & Trends

At the end of FY2020, Summit Therapeutics reported Non-Current Deffered Revenue of $569,000, up 15.4% from FY2019.

  • Across earlier years, Non-Current Deffered Revenue came in at $493,000 in FY2019.
  • Per Business Quant, the preceding three quarters came in at $383,000 (Q1 2021), $569,000 (Q4 2020) and $715,000 (Q3 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn -
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn -
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn -
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn -
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn -
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn -
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn -
10 Summit Therapeutics 13.24 Bn 11.00 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 365,000.00
Mar 31, 2021 383,000.00
Dec 31, 2020 569,000.00
Sep 30, 2020 715,000.00
Dec 31, 2019 493,000.00
API Access

Summit Therapeutics Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=SMMT&period=max&api_key=YOUR_API_KEY